Objective To investigate the role of subdural puncture(SDP)in the diagnosis and treatment of subdural fluid collection in young children with purulent meningitis.Methods Totally 207

Cerebral Palsy ; diagnosis ; etiology ; therapy ; Humans ; Magnetic Resonance Imaging ; Prognosis

Humans ; Temporomandibular Joint Disorders ; therapy

AIM: To investigate the expression of Fas/FasL system in human lung carcinoma cell lines (A549, EBC-1, LCSC) and T-lymphocytes (Jurkat), and to search the possibilities of immune escape and counterattack mediated by Fas/FasL pathway in human lung carcinoma cells. METHODS: The protein and mRNA expression of Fas and FasL were detected by FACScan, RT-PCR, respectively. Cell apoptosis was assessed by fluorescent staining. Cell growth was determined by a trypan blue exclusion assay. RESULTS: Fas and FasL were expressed in 3 human lung carcinoma cell lines and T-cells, Jurkat. The lung carcinoma cells inhibited the growth (P

Adolescent ; Asthma ; blood ; drug therapy ; Case-Control Studies ; Child ; Child, Preschool ; Female ; Humans ; Interleukin-17 ; blood ; Male

Adult ; Female ; Humans ; Male ; Middle Aged ; Parathyroid Neoplasms ; diagnostic imaging ; surgery ; Retrospective Studies ; Ultrasonography

Humans ; Quality of Life ; Rhinitis ; Sinusitis

Objective: To study the chemical constituents of Hedyotis tenelliflora. Methods: The compounds were isolated by chromatographic separation technology. The structures were identified on the basis of physicochemical and spectral data. Results: Four iridoid glycosides were isolated from the whole plant of H. tenelliflora. On the basis of the chemical and spectral methods, their structures were elucidated as teneoside C (1), harpagoside (2), harpagide (3), and asperulosidic acid (4). Conclusion: Compound 1 is a new compound from H. tenelliflora, and compounds 2 and 3 are found for the first time in the plants of Hedyotis L.

Objective To compare the effectiveness and safety of recombinant luteinizing hormone (rLH) combined with recombinant follicle-stimulating hormone (rFSH) and rFSH alone in women undergoing in vitro fertilisation/intracytoplasmic sperm microinjection (IVF/ICSI) applied gonadotrophin-releasing hormone (GnRH) antagonist. Methods The databases including PubMed, Embase, Cochrane Library, ClinicalTrials.gov, CNKI, VIP and Wanfang Data were electronically searched to collect the randomized controlled trials (RCT) applied GnRH antagonist using rLH+rFSH or rFSH alone in IVF/ISCI cycles from inception to Dec. 2018. Following the Cochrane system evaluation and according to the criteria for inclusion and exclusion, two reviewers independently screened literature, extracted data and evaluated the bias risk for inclusion in studies, and then meta-analysis was conducted by RevMan 5.3 software. Results A total of 10 RCT studies involving 1965 patients were included, of them 988 cases in rFSH+rLH group and 977 cases in rFSH alone group. Meta-analysis showed no significant difference between rFSH alone group and rLH+rFSH group in clinical pregnancy rate (RR=1.02, 95%CI 0.82-1.27, P=0.85), ongoing pregnancy rate (RR=1.06, 95%CI 0.86-1.32, P=0.57), miscarriage rate (RR=1.38, 95%CI 0.75-2.54, P=0.29), incidence of adverse events canceled due to ovarian hyporesponsiveness (RR=0.90, 95%CI 0.42-1.93, P=0.78), and the incidence of adverse events canceled due to ovarian hyperstimulation syndrome (OHSS) (RR=1.06, 95%CI 0.56-1.99, P=0.86). Conclusions Current evidence shows that, compared with rFSH alone group, the rLH+rFSH group showed no effect on the clinical pregnancy rate, ongoing pregnancy rate, miscarriage rate, incidence of adverse events canceled due to ovarian hyporesponsiveness, and the incidence of adverse events canceled due to OHSS. The above conclusions need to be verified by more high quality research since the quality and quantity limited of included studies.